Anti-neoplastic combined pharmaceutical composition and application thereof

Abstract

An anti-neoplastic combined pharmaceutical composition and application thereof. The combined pharmaceutical composition is prepared from plasmodia and chemotherapeutic drugs. The combined pharmaceutical composition combines chemotherapy with Plasmodium immunotherapy, has high biosafety, has stronger antineoplastic activity than single chemotherapy or single Plasmodium immunotherapy, can prolong the lifetime of cancer patients, and provides a new strategy and idea for cancer treatment. Moreover, the dosage of the chemotherapy drugs can be reduced, toxic and side effects caused by the chemotherapy drugs are reduced, and treatment costs of tumor patients are reduced. In addition, the combined pharmaceutical composition can promote release of a tumor antigen, induces a stronger anti-tumor specific immune response, and exerts the continuous synergistic effect of immunotherapy and chemotherapy.

1 . An anti-tumor combined pharmaceutical composition, comprising  Plasmodium  and a chemotherapeutic agent. 
     
     
         2 . The combined pharmaceutical composition according to  claim 1 , wherein the  Plasmodium  comprises any one or a combination of at least two of  Plasmodium  falciparum,  Plasmodium  vivax,  Plasmodium  malariae,  Plasmodium ovale  or  Plasmodium knowlesi , preferably  Plasmodium falciparum  or  Plasmodium  vivax. 
     
     
         3 . The combined pharmaceutical composition according to  claim 1 , wherein the chemotherapeutic agent comprises an alkylating agent-based chemotherapeutic agent, an anti-metabolic chemotherapeutic agent, an antibiotic-based chemotherapeutic agent, an animal or plant chemotherapeutic agent, a miscellaneous chemotherapeutic agent or an HIV protease inhibitor. 
     
     
         4 . The combined pharmaceutical composition according to  claim 3 , wherein the alkylating agent-based chemotherapeutic agent comprises cyclophosphamide or ifosfamide;
 preferably, the anti-metabolic chemotherapeutic agent comprises gemcitabine, pemetrexed, 5-fluorouracil, cytarabine or methotrexate;   preferably, the antibiotic-based chemotherapeutic agent comprises mitomycin, doxorubicin or actinomycin D;   preferably, the animal or plant chemotherapeutic agent comprises etoposide, docetaxel, paclitaxel, vincristine or irinotecan;   preferably, the miscellaneous chemotherapeutic agent comprises cis-platinum, carboplatin, oxaliplatin or asparaginase;   preferably, the HIV protease inhibitor comprises nelfinavir, saquinavir, indinavir or ritonavir.   
     
     
         5 . The combined pharmaceutical composition according to  claim 1 , comprising  Plasmodium  and gemcitabine;  Plasmodium  and cyclophosphamide;  Plasmodium  and cyclophosphamide;  Plasmodium  and pemetrexed;  Plasmodium  and cis-platinum;  Plasmodium  and mitomycin;  Plasmodium  and docetaxel;  Plasmodium  and etoposide; or  Plasmodium  and nelfinavir. 
     
     
         6 . The combined pharmaceutical composition according to  claim 1 , wherein the combined pharmaceutical composition is in a dosage form that comprises any pharmaceutically acceptable dosage form. 
     
     
         7 . The combined pharmaceutical composition according to  claim 1 , further comprising any one or a combination of at least two of pharmaceutically acceptable adjuvants. 
     
     
         8 . The combined pharmaceutical composition according to  claim 1 , wherein the combined pharmaceutical composition is a single compound preparation. 
     
     
         9 . The combined pharmaceutical composition according to  claim 1 , wherein the combined pharmaceutical composition is a combination of a separate  Plasmodium  preparation and a separate preparation of the chemotherapeutic agent. 
     
     
         10 . The combined pharmaceutical composition according to  claim 9 , wherein the separate  Plasmodium  preparation and the separate preparation of the chemotherapeutic agent are administered simultaneously or sequentially. 
     
     
         11 . The combined pharmaceutical composition according to  claim 1 , wherein the combined pharmaceutical composition is administered by a route that comprises intravenous injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, oral administration, sublingual administration, nasal administration or percutaneous administration, preferably intravenous injection or oral administration. 
     
     
         12 . The combined pharmaceutical composition according to  claim 1 , wherein the combined pharmaceutical composition is loaded on a pharmaceutical carrier. 
     
     
         13 . The combined pharmaceutical composition according to  claim 12 , wherein the pharmaceutical carrier comprises a liposome, a micelle, a dendrimer, a microsphere or a microcapsule. 
     
     
         14 . A method for treating tumor, comprising administering an effective amount of the combined pharmaceutical composition according to  claim 1  to a subject in need thereof. 
     
     
         15 . The method according to  claim 14 , wherein tumor comprises lung cancer, gastric cancer, colon cancer, liver cancer, breast cancer or pancreatic cancer.